Beclomethasone Dipropionate

Dosage for Beclomethasone Dipropionate is highly individualized based on the severity of the condition and the specific formulation used.

• For Chronic Asthma (Inhalation): The typical starting dose for adults who have not previously used steroids is often 40 mcg to 80 mcg twice daily. For those transitioning from other inhaled corticosteroids, the dose may range from 40 mcg to 320 mcg twice daily. The maximum recommended dose is usually 640 mcg per day (320 mcg twice daily).
• For Allergic Rhinitis (Nasal Spray): The standard adult dose is typically 1 to 2 inhalations (42 mcg to 84 mcg) in each nostril twice daily. Some newer formulations allow for once-daily dosing (e.g., 2 sprays per nostril once daily).
• For Ulcerative Colitis (Oral): A common dose for inducing remission is 5 mg once daily, usually taken in the morning, for a duration of up to 4 weeks.

• Asthma (Ages 4-11): The standard starting dose is often 40 mcg twice daily. The maximum dose for this age group generally does not exceed 80 mcg twice daily.
• Allergic Rhinitis (Ages 6-12): The typical dose is 1 inhalation in each nostril twice daily. Use in children under 6 years of age for rhinitis or under 4 years for asthma must be specifically directed by a pediatrician.
• Growth Monitoring: Healthcare providers will monitor the growth of children taking any form of corticosteroid long-term, as these medications can potentially slow growth rates in some pediatric patients.

Renal Impairment

Specific dosage adjustments for patients with kidney disease are generally not required for inhaled or nasal Beclomethasone Dipropionate, as systemic absorption is low. However, patients with severe renal impairment should be monitored for systemic corticosteroid effects if taking oral formulations.

Hepatic Impairment

Because the liver is involved in the metabolism of the swallowed portion of the drug and the clearance of the active metabolite, patients with significant liver disease (e.g., cirrhosis) may experience higher systemic levels. While specific dose reduction protocols are not standardized for inhalers, clinical monitoring for signs of hypercorticism (Cushingoid features) is recommended.

Elderly Patients

No overall differences in safety or effectiveness have been observed between elderly patients and younger patients. However, because older adults are more prone to decreased bone mineral density and cataracts, the lowest effective dose should be prioritized.

Proper technique is critical for the efficacy of Beclomethasone Dipropionate:

1. 1Inhalers: If using an MDI, shake the canister well (if required by the specific brand). Exhale fully, place the mouthpiece in your mouth, and inhale deeply while depressing the canister. Hold your breath for about 10 seconds.
2. 2Rinsing: CRITICAL STEP: Always rinse your mouth with water and spit it out after using an asthma inhaler. This helps prevent 'thrush' (a yeast infection of the mouth).
3. 3Nasal Spray: Gently blow your nose before use. Tilt your head slightly forward, insert the tip into a nostril, and point it slightly away from the center of the nose (the septum). Spray while breathing in gently through the nose.
4. 4Consistency: This medication must be used at regular intervals to be effective. Do not skip doses even if you feel well.
5. 5Storage: Store at room temperature (15°C to 30°C or 59°F to 86°F). Keep the canister away from open flames or high heat, as it is under pressure.

If you miss a dose, take it as soon as you remember. If it is almost time for your next scheduled dose, skip the missed dose and resume your regular schedule. Do not double the dose to catch up.

Acute overdose of inhaled Beclomethasone Dipropionate is unlikely to be life-threatening. However, chronic over-utilization can lead to systemic corticosteroid effects, such as HPA (hypothalamic-pituitary-adrenal) axis suppression, which can cause extreme fatigue, muscle weakness, and fainting. If someone swallows the contents of a canister or takes an excessive amount of oral tablets, contact a poison control center or seek emergency medical care immediately.

> Important: Follow your healthcare provider's dosing instructions precisely. Do not adjust your dose or stop the medication without medical guidance, as sudden discontinuation can lead to a return of symptoms.

Side effects of Beclomethasone Dipropionate are often localized to the site of administration. For inhaled versions, the most common issues include:

• Oral Candidiasis (Thrush): This appears as white patches on the tongue or inner cheeks. It can cause soreness or a cotton-like feeling in the mouth. Rinsing after use significantly reduces this risk.
• Dysphonia (Hoarseness): A change in the sound of your voice or difficulty speaking, caused by the local effect of the steroid on the vocal cords.
• Sore Throat and Cough: Mild irritation of the upper airway immediately following inhalation.
• Nasal Irritation: For nasal sprays, patients frequently report stinging, burning, or dryness inside the nose.

• Epistaxis (Nosebleeds): Particularly common with prolonged use of nasal sprays.
• Headache: Often reported shortly after administration.
• Unpleasant Taste or Smell: A transient metallic or medicinal taste following a nasal or oral dose.
• Dry Mouth: Reduced salivation leading to discomfort.

• Nasal Septal Perforation: A hole in the wall between the nostrils, usually resulting from improper nasal spray technique over a long period.
• Increased Intraocular Pressure: Steroids can occasionally increase the pressure inside the eye.
• Hypersensitivity Reactions: Including rash, urticaria (hives), and angioedema (swelling of the face or throat).

> Warning: Stop taking Beclomethasone Dipropionate and call your doctor immediately if you experience any of these.

• Anaphylaxis: Signs include difficulty breathing, severe rash, swelling of the tongue, and fainting. This is a medical emergency.
• Paradoxical Bronchospasm: Occasionally, an inhaled dose can cause an immediate tightening of the airways (wheezing) right after use. This requires immediate use of a rescue inhaler.
• Adrenal Insufficiency: If you are switching from oral prednisone to inhaled beclomethasone, you may experience signs of adrenal failure, such as extreme dizziness, nausea, and profound weakness.
• Vision Changes: Blurred vision, seeing halos around lights, or eye pain may indicate the development of glaucoma or cataracts.
• Severe Infections: Corticosteroids can weaken the immune response. Seek help for high fever, chills, or persistent sore throat that does not resolve.

Chronic use of Beclomethasone Dipropionate, especially at high doses, may lead to systemic absorption and the following long-term effects:

• Bone Mineral Density Reduction: Long-term steroid use is associated with an increased risk of osteoporosis (brittle bones). Patients at high risk may require calcium and Vitamin D supplementation.
• Growth Retardation in Children: As noted previously, systemic absorption can slightly delay growth. Pediatricians will monitor height and weight closely.
• Skin Thinning: Increased bruising and thinning of the skin (atrophy) can occur, though this is more common with oral steroids than inhaled ones.
• Psychological Effects: Though rare with inhaled forms, some patients report mood swings, anxiety, or sleep disturbances.

No FDA black box warnings for Beclomethasone Dipropionate. However, there are significant warnings regarding the transfer of patients from systemic corticosteroid therapy (like prednisone) to inhaled Beclomethasone. Deaths due to adrenal insufficiency have occurred in asthmatic patients during and after transfer from systemic corticosteroids to less systemically available inhaled corticosteroids. During times of stress or a severe asthma attack, patients who have been transferred require immediate resumption of systemic steroids.

Report any unusual symptoms to your healthcare provider. Your doctor will weigh the benefits of inflammation control against these potential side effects.

Beclomethasone Dipropionate is a long-term maintenance medication. It is not a bronchodilator and should never be used as a rescue medication for acute asthma attacks (bronchospasm). Patients must always have a fast-acting rescue inhaler (such as albuterol) available for sudden symptoms.

No FDA black box warnings for Beclomethasone Dipropionate. The most critical safety concern remains the risk of adrenal crisis when transitioning from oral steroids to inhaled forms, as the inhaled form does not provide the systemic steroid levels the body may have become dependent upon.

• Adrenal Suppression: High doses or prolonged use can suppress the body's natural production of cortisol. This can lead to a life-threatening adrenal crisis during periods of physical stress, such as surgery, trauma, or severe infection.
• Immunosuppression: Corticosteroids can mask signs of infection and may worsen existing infections. Patients who have not had chickenpox or measles should avoid exposure, as these illnesses can be more severe in patients on steroids.
• Ocular Effects: Long-term use has been linked to the development of glaucoma and cataracts. Regular eye exams are recommended for those on high-dose maintenance therapy.
• Candida Albicans Infection: As mentioned, localized fungal infections in the mouth and pharynx are common. If an infection develops, it should be treated with appropriate local or systemic antifungal therapy while continuing the steroid, or as directed by a doctor.
• Reduction in Bone Density: Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, or use of other medications that can reduce bone mass (e.g., anticonvulsants), should be monitored closely.

Patients on long-term Beclomethasone Dipropionate may require the following monitoring:

• Growth Velocity: In pediatric patients.
• Ophthalmic Exams: To check for cataracts and glaucoma.
• Bone Mineral Density (BMD): In patients at risk for osteoporosis.
• HPA Axis Testing: (e.g., ACTH stimulation test) if adrenal suppression is suspected due to high-dose use or symptoms of insufficiency.

Beclomethasone Dipropionate generally does not affect the ability to drive or operate machinery. However, if a patient experiences rare side effects like dizziness or vision changes, they should refrain from these activities until the symptoms resolve.

There is no direct contraindication between alcohol and inhaled Beclomethasone Dipropionate. However, for patients taking oral formulations for ulcerative colitis, alcohol may irritate the gastrointestinal tract and worsen the underlying condition. Consult your doctor regarding safe alcohol consumption levels.

Do not stop taking Beclomethasone Dipropionate abruptly. Sudden discontinuation can lead to a flare-up of asthma or rhinitis symptoms. If a patient has been on high doses, the healthcare provider will typically implement a tapering schedule to allow the adrenal glands to resume normal function.

> Important: Discuss all your medical conditions, especially any history of tuberculosis, untreated infections, or recent surgery, with your healthcare provider before starting Beclomethasone Dipropionate.

While there are few absolute contraindications for inhaled Beclomethasone, it should not be used with:

• Desmopressin: Using systemic or high-dose topical steroids with desmopressin may increase the risk of water retention and severe hyponatremia (low blood sodium).

• Strong CYP3A4 Inhibitors: Medications such as Ritonavir, Atazanavir, Ketoconazole, and Itraconazole can inhibit the enzyme responsible for breaking down Beclomethasone. This can lead to increased systemic concentrations of the steroid, potentially causing Cushing’s syndrome or adrenal suppression.
• Other Corticosteroids: Taking Beclomethasone alongside oral prednisone or dexamethasone increases the cumulative steroid load, significantly raising the risk of systemic side effects like bone loss and immune suppression.

• Aldesleukin: Corticosteroids may reduce the anti-tumor effectiveness of Aldesleukin.
• Mifepristone: This medication is a glucocorticoid receptor antagonist and will reduce the effectiveness of Beclomethasone.
• Live Vaccines: Because steroids can suppress the immune system, the body may not respond appropriately to a live vaccine (e.g., MMR, Varicella), or the vaccine virus could replicate more than intended. Consult your doctor before receiving any vaccinations.

• Grapefruit Juice: While primarily a concern for oral medications, grapefruit juice can inhibit CYP3A4 in the gut and liver. For patients taking oral Beclomethasone (Clipper), this could increase drug levels. It is generally best to avoid large amounts of grapefruit products while on oral steroid therapy.
• Sodium/Salt: Steroids can cause the body to retain sodium and water. Patients on high doses may be advised to monitor their salt intake to prevent swelling (edema) or high blood pressure.

• St. John’s Wort: This herb is a potent inducer of CYP3A4 and may decrease the plasma concentration of Beclomethasone, potentially reducing its efficacy.
• Echinacea: Some believe Echinacea stimulates the immune system, which may theoretically interfere with the immunosuppressive goals of corticosteroid therapy.
• Licorice Root: Natural licorice contains glycyrrhizic acid, which can mimic some steroid effects and potentially worsen side effects like potassium loss.

• Skin Tests: Beclomethasone may suppress the reaction to allergen skin tests. It is usually recommended to stop the medication several days before testing if possible, under a doctor's guidance.
• Plasma Cortisol Levels: Long-term or high-dose use may result in lower-than-normal results on morning plasma cortisol tests due to HPA axis suppression.

For each major interaction, the management strategy usually involves dose adjustment or increased clinical monitoring for systemic steroid effects.

> Important: Tell your doctor about ALL medications, including over-the-counter drugs, vitamins, and herbal products you are taking. A complete list helps prevent dangerous interactions.

Beclomethasone Dipropionate must NEVER be used in the following circumstances:

1. 1Status Asthmaticus: This is a severe, life-threatening asthma attack that does not respond to standard treatments. Beclomethasone is a slow-acting maintenance drug and cannot open airways quickly enough in an emergency.
2. 2Primary Treatment of Acute Bronchospasm: It is not a rescue inhaler. Using it during an acute attack instead of a bronchodilator can lead to respiratory failure.
3. 3Hypersensitivity: Patients with a known severe allergy to Beclomethasone Dipropionate or any of the ingredients in the formulation (such as milk proteins in some dry powder inhalers) must avoid it. Reactions can include anaphylaxis or severe bronchospasm.
4. 4Untreated Systemic Infections: This includes untreated fungal, bacterial, viral, or parasitic infections (such as ocular herpes simplex), as the drug's immunosuppressive effects can allow the infection to spread unchecked.

Conditions requiring careful risk-benefit analysis include:

• Active or Quiescent Tuberculosis: Steroids can reactivate TB infections in the respiratory tract.
• Recent Nasal Surgery or Trauma: For nasal sprays, steroids can inhibit wound healing. The drug should not be used until healing has occurred.
• Osteoporosis: Because steroids can further decrease bone density, the necessity of the drug must be weighed against the risk of fractures.
• Glaucoma or Cataracts: Patients with pre-existing eye conditions require more frequent monitoring.

Patients who have had allergic reactions to other corticosteroids (such as Fluticasone, Budesonide, or Mometasone) may be at an increased risk of reacting to Beclomethasone. While not always cross-reactive, a history of 'steroid allergy' should be discussed with an allergist before starting treatment.

> Important: Your healthcare provider will evaluate your complete medical history, including any history of infections or eye problems, before prescribing Beclomethasone Dipropionate.

FDA Pregnancy Category C (under the older system). There are no adequate and well-controlled studies in pregnant women. However, poorly controlled asthma during pregnancy poses significant risks to both the mother (preeclampsia, gestational hypertension) and the fetus (premature birth, low birth weight).

Data from observational studies suggest that inhaled Beclomethasone is generally considered one of the preferred corticosteroids for managing asthma during pregnancy when a steroid is necessary. However, it should only be used if the potential benefit justifies the potential risk to the fetus. Infants born to mothers who received substantial doses of corticosteroids during pregnancy should be carefully observed for signs of hypoadrenalism (underactive adrenal glands).

It is not known whether Beclomethasone Dipropionate is excreted in human milk. However, other corticosteroids are known to pass into breast milk in small amounts. Because the systemic levels of Beclomethasone are very low following inhalation or nasal administration, the amount a nursing infant would receive is likely negligible. Nevertheless, caution should be exercised, and breastfeeding mothers should discuss the timing of their doses and the health of their infants with a pediatrician.

Beclomethasone Dipropionate is approved for use in children (typically aged 4 and older for asthma, and 6 and older for nasal symptoms). The primary concern in this population is the potential for growth suppression. Clinical trials have shown that inhaled corticosteroids can cause a reduction in growth velocity (approximately 1 cm per year) in pediatric patients. To minimize this risk, the 'step-down' approach is used—titrating to the lowest dose that maintains effective control of symptoms.

Clinical studies have not identified specific differences in response between the elderly and younger adults. However, older patients are at higher risk for side effects such as skin thinning, bruising, and bone loss. Additionally, older patients may have more difficulty with the coordination required for metered-dose inhalers. Healthcare providers may recommend the use of a spacer device or a breath-actuated inhaler (like the RediHaler) to ensure proper delivery.

No formal studies have been conducted in patients with renal impairment. However, since only a small fraction of the drug is excreted renally, dose adjustments are typically unnecessary. For patients on dialysis, the drug is not expected to be significantly cleared, but systemic levels remain low enough that this is rarely a clinical concern.

In patients with severe hepatic impairment, the clearance of the swallowed portion of the drug and its metabolites may be reduced. This could lead to higher systemic levels and an increased risk of HPA axis suppression. Patients with liver disease should be monitored for signs of systemic steroid excess, such as facial swelling, easy bruising, or high blood sugar.

> Important: Special populations require individualized medical assessment to ensure the dosage is safe and effective for their specific physiological needs.

Beclomethasone Dipropionate is a potent glucocorticoid receptor agonist. It is a prodrug with weak receptor affinity that is rapidly converted by esterases to beclomethasone-17-monopropionate (17-BMP), which has a high affinity for glucocorticoid receptors. The 17-BMP metabolite works by binding to the glucocorticoid receptor in the cytoplasm. The resulting complex moves into the nucleus and binds to GREs, leading to the suppression of inflammatory genes (like those for IL-6 and TNF-alpha) and the induction of anti-inflammatory genes (like Annexin A1). This results in reduced airway edema, decreased mucus secretion, and inhibited recruitment of inflammatory cells.

Beclomethasone Dipropionate has a slow onset of action. Improvement in asthma control can occur within 24 hours of starting treatment, but maximum improvement may take 1 to 2 weeks or longer. It does not have an immediate bronchodilatory effect. The duration of effect is sufficient for twice-daily dosing in most patients. Tolerance to the anti-inflammatory effects of corticosteroids is generally not observed, though the underlying disease severity may change over time.

| Parameter | Value |

|---|---|

| Bioavailability | <20% (Inhaled systemic), ~15% (Oral) |

| Protein Binding | 94% to 96% |

| Half-life (17-BMP) | 2.8 hours (Plasma), up to 15 hours (Terminal) |

| Tmax | 0.5 to 2 hours (for 17-BMP) |

| Metabolism | Primarily via esterases to 17-BMP; CYP3A4 for further metabolism |

| Excretion | Fecal 60%, Renal 12% |

• Molecular Formula: C28H37ClO7
• Molecular Weight: 521.0 g/mol
• Solubility: Practically insoluble in water; very soluble in chloroform; freely soluble in acetone and in alcohol.
• Description: It is a white to creamy white, odorless crystalline powder. Chemically, it is 9-chloro-11β,17,21-trihydroxy-16β-methylpregna-1,4-diene-3,20-dione 17,21-dipropionate.

Beclomethasone Dipropionate is classified as a synthetic corticosteroid and a glucocorticoid receptor agonist. Within respiratory medicine, it is categorized as an Inhaled Corticosteroid (ICS). Related medications in this class include Fluticasone Propionate, Budesonide, and Mometasone Furoate.